

Prof. YÜKSEL ÜRÜN

Personal Information

Office Phone: [+90 595 711 2](tel:+905957112)

Email: urun@ankara.edu.tr

Web: <https://avesis.ankara.edu.tr/urun>

International Researcher IDs

ORCID: 0000-0002-9152-9887

Publons / Web Of Science ResearcherID: AAQ-3612-2020

ScopusID: 11540730500

Yoksis Researcher ID: 172747

Biography

Dr. Yüksel Ürün, Ankara Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Anabilim Dalı'nda profesör olarak görev yapmaktadır. 2009 yılından beri Ankara Üniversitesi Tıp Fakültesi'nin bir parçası olan Dr. Ürün, aynı kurumda tıbbi onkoloji alanındaki klinik fellowship eğitimini tamamlamıştır. Fellowship eğitimini tamamladıktan sonra Dr. Ürün, Prof. Toni Choueiri'nin mentorluğunda Amerika Birleşik Devletleri, Boston'daki Harvard Tıp Okulu'na bağlı Dana Farber Kanser Enstitüsü'nde araştırma fellowu olarak değerli araştırma deneyimi kazanmıştır.

Türkiye'ye döndükten sonra Dr. Ürün, Türk Onkoloji Grubu Böbrek Kanseri Konsorsiyumu'nu (TKCC) kurmuş ve Türk Tıbbi Onkoloji Derneği'nin ürogenital kanserler rehberlik grubunu yönetmiştir. EORTC GU grubu, Advanced Prostat Kanseri Konsensüs Konferansı (APCCC) gibi çeşitli uluslararası ve ulusal onkoloji organizasyonlarının aktif bir üyesidir. Aynı zamanda ESMO Ürogenital Tümörler ve Prostat grubunun fakülte üyeliğini üstlenmiş, ESMO Klinik Tıp Komitesi'nde görev almıştır. Ayrıca, Amerikan Klinik Onkoloji Derneği'nin (ASCO) 2023-2024 Liderlik Geliştirme Programı sınıfına da katılmaktadır.

Dr. Ürün'ün araştırma ilgi alanları ürogenital kanserlerin epidemiyolojisi, tanısı, biyobelirteçleri, meta-analizi ve tedavi sonuçlarını içermektedir. Birçok klinik çalışmanın baş araştırmacısı olan Dr. Ürün, 100'den fazla hakemli makale, sunum ve kitap bölümü yayımlamıştır. Dr. Ürün, hasta bakımını iyileştirmeye, eğitimde çeşitliliği ve eşitliği desteklemeye ve klinik çalışmalarda temsil edilmeyen grupların katılımını artırmaya olan bağlılığıyla tanınmaktadır.

Education Information

Post Doctorate of Medicine, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2009 - 2012

Expertise In Medicine, Diğer (Kurumlar,hastaneler Vb.), Hastaneler, Ankara Numune Eğitim Ve Araştırma Hastanesi, Turkey 2002 - 2007

Undergraduate, Hacettepe University, Tıp Fakültesi, Tıp Pr., Turkey 1995 - 2002

Dissertations

Post Doctorate of Medicine, Trastuzumab ile tedavi edilen meme kanserli hastalarda kardiyotoksitenin erken belirlenmesinde serum biyobelirteçlerinin rolü, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2012
Expertise In Medicine, GERM HÜCRELİ TÜMÖRLERİN RETROSPEKTİF DEĞERLENDİRİLMESİ, Diğer (Kurumlar,hastaneler Vb.), 2007

Research Areas

Health Sciences

Academic Titles / Tasks

Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2022 - Continues

Associate Professor, Ankara University, Kanser Araştırma Enstitüsü, Klinik Onkoloji Anabilim Dalı, 2019 - 2022

Associate Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2015 - 2022

Expert, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2009 - 2012

Academic and Administrative Experience

Assistant Director of the Institute, Ankara University, Kanser Araştırma Enstitüsü, Klinik Onkoloji Anabilim Dalı, 2020 - Continues

Advising Theses

ÜRÜN Y., İmmün Denetim Noktası İnhibitörü Tedavisi Alan Hastalarda Tedavi Yanıtı ile İlişkili Faktörlerin Araştırılması, Expertise In Medicine, M.BERİL(Student), 2021

ÜRÜN Y., Metastatik böbrek hücreli kanser hastalarında sarkopeninin tedavi yanıtı ve toleransına etkisi, Expertise In Medicine, B.MİROĞLU(Student), 2020

ÜRÜN Y., Testis germ hücre tümörlü hastalarda kemoterapinin immün yaşlanmadaki rolü, Postgraduate, T.ÜNVER(Student), 2020

ÜRÜN Y., Metastatik ürotelyal kanserlerde sağkalımla ilişkili prognostik faktörlerin belirlenmesi, Expertise In Medicine, S.BALLI(Student), 2019

ÜRÜN Y., Tirozin kinaz inhibitörü ile tedavi edilen renal hücreli kanser olgularında sistemik immün inflamasyon indeksinin tedavi yanıtı ile ilişkisi, Expertise In Medicine, K.BİR(Student), 2017

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617**
YAZGAN S. C., YEKEDÜZ E., ARAZ M., BÖLEK H., KÜÇÜK N. Ö., ÜRÜN Y.
Prostate, vol.85, no.1, pp.90-96, 2025 (SCI-Expanded)
- II. **Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer**
Tural D., Arslan C., Selcukbiricik F., ÖLMEZ Ö. F., Akar E., ERMAN M., ÜRÜN Y., Erdem D., Kilickap S.
Clinical Genitourinary Cancer, vol.22, no.6, 2024 (SCI-Expanded)
- III. **Effectiveness of androgen receptor pathway inhibitors and proton pump inhibitors.**
Yazgan S. C., Yekedüz E., ÜRÜN Y.
The Prostate, vol.84, no.16, pp.1537, 2024 (SCI-Expanded)
- IV. **Primary Prostatic Stromal Sarcoma: A Case Report and Review of the Literature**
Erul E., GÜLPINAR Ö., KURU ÖZ D., BERBER H., KİREMİTÇİ S., ÜRÜN Y.
MEDICINA-LITHUANIA, vol.60, no.12, 2024 (SCI-Expanded)
- V. **Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives**
Akkus E., Arslan Ç., ÜRÜN Y.

Cancer Treatment Reviews, vol.130, 2024 (SCI-Expanded)

- VI. **Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study**
Fiala O., Massari F., Basso U., Giannatempo P., Grande E., Buti S., Myint Z. W., De Giorgi U., Pichler R., Grillone F., et al.
Targeted Oncology, vol.19, no.6, pp.905-915, 2024 (SCI-Expanded)
- VII. **Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors**
Tural D., Arslan C., Selcukbiricik F., ÖLMEZ Ö. F., ERMAN M., ÜRÜN Y., Erdem D., Kilickap S.
Clinical Genitourinary Cancer, vol.22, no.5, 2024 (SCI-Expanded)
- VIII. **Applying genomic analysis to refine unclassified renal cell carcinoma**
Yekeduz E., Braun D. A., El Hajj Chehade R., Eid M., Labaki C., Machaalani M., Nassar A., Nawfal R., Saad E., Saliby R. M., et al.
ONCOLOGIST, 2024 (SCI-Expanded)
- IX. **Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study**
Sekmek S., Karahan I., Ucar G., Ceylan F., Bayram D., Seven I., BÖLEK H., ÜRÜN Y., Yücel K. B., YAZICI O., et al.
Clinical and Translational Oncology, vol.26, no.8, pp.1878-1885, 2024 (SCI-Expanded)
- X. **The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer**
Yildirim H. C., Buyukkor M., KAVGACI G., Celik B. Ş., Yucel K. B., DURSUN B., Chalabiyev E., Yilmaz F., Yildirim S. S., KUŞ F., et al.
Medicine (United States), vol.103, no.30, 2024 (SCI-Expanded)
- XI. **Perceptions and expectations: A study on prognostic perception and quality of life in patients with metastatic renal and bladder cancer.**
Bolek H., Arslan C., Basaran M., Cicin I., Ozguroglu M., Tural D., Urun Y.
JOURNAL OF CLINICAL ONCOLOGY, no.16, 2024 (SCI-Expanded)
- XII. **Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG).**
YAŞAR H. A., Aktas B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., Sakin A., Ates O., Basoglu T., Arslan C., et al.
Clinical genitourinary cancer, vol.22, no.3, pp.102077, 2024 (SCI-Expanded)
- XIII. **Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis.**
YAZGAN S. C., AKKUŞ E., Yekeduz E., ÜRÜN Y.
Critical reviews in oncology/hematology, vol.198, pp.104376, 2024 (SCI-Expanded)
- XIV. **Applying genomic analysis to refine unclassified renal cell carcinoma**
Yekeduz E., Braun D. A., Chehade R. E. H., Eid M., Labaki C., Machaalani M., Nassar A., Nawfal R., Saad E., Saliby R. M., et al.
JOURNAL OF CLINICAL ONCOLOGY, no.16, 2024 (SCI-Expanded)
- XV. **Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape**
Ghose A., Lapitan P., Apte V., Ghosh A., Kandala A., Basu S., Parkes J., Shinde S. D., Boussios S., Sharma A., et al.
Current Oncology Reports, vol.26, no.6, pp.633-646, 2024 (SCI-Expanded)
- XVI. **Characterization of complete responders to nivolumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial**
Galsky M. D., Sonpavde G. P., Powles T., Claps M., Burotto M., Schenker M., Sade J. P., Bamias A., Beuzeboc P., Bedke J., et al.
JOURNAL OF CLINICAL ONCOLOGY, no.16, 2024 (SCI-Expanded)
- XVII. **Unveiling the Role of Human Papillomavirus in Urogenital Carcinogenesis a Comprehensive Review**
KARAOĞLAN B. B., ÜRÜN Y.
Viruses, vol.16, no.5, 2024 (SCI-Expanded)
- XVIII. **Accuracy and usability of artificial intelligence chatbot generated chemotherapy protocols**
ERDAT E. C., Yalciner M., ÜRÜN Y.

FUTURE ONCOLOGY, 2024 (SCI-Expanded)

- XIX. Impact of antihistamine use on the survival outcomes of immune checkpoint inhibitors in advanced cancer patients.**
Eylemer Mocan E., Yekedüz E., Karataş G., Yazgan S. C., Köksoy E. B., Çay Şenler F., Utkan G., Demirkazık A., Akbulut H., Ürün Y.
Anti-cancer drugs, vol.35, no.2, pp.190-194, 2024 (SCI-Expanded)
- XX. Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (mUC): results from the phase 3 CheckMate 901 trial**
Bedke J., van der Heijden M. S., Sonpavde G., Powles T., Necchi A., Burotto M., Schenker M., Sade J. P., Bamias A., Beuzeboc P., et al.
ONCOLOGY RESEARCH AND TREATMENT, pp.230, 2024 (SCI-Expanded)
- XXI. Exploring the connection between microsatellite instability and inflammatory indicators in cancers**
Karaoglan B. B., SAVAŞ B., Utkan G., Urun Y.
FUTURE ONCOLOGY, no.2, pp.95-105, 2024 (SCI-Expanded)
- XXII. Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors.**
KARAOĞLAN B. B., Yekedüz E., YAZGAN S. C., Mocan E. E., KÖKSOY E. B., YAŞAR H. A., Şenler F., UTKAN G., DEMİRKAZIK A., AKBULUT H., et al.
Immunotherapy, vol.16, no.12, pp.821-828, 2024 (SCI-Expanded)
- XXIII. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study**
GÜVEN D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvacı K., Dursun B., Celayir M., Chelebiyev E., Nayir E., ERMAN M., et al.
CANCER MEDICINE, vol.13, no.1, 2024 (SCI-Expanded)
- XXIV. Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments**
BALLI S., BÖLEK H., ÜRÜN Y.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2024 (SCI-Expanded)
- XXV. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study**
Karadurmus N., Kaplan M. A., Sendur M. A. N., ÜRÜN Y., Demirci U., Karaca S. B., Goktas Aydin S., Aykan M. B., Bilici A., Sezer A., et al.
Current Medical Research and Opinion, vol.40, no.7, pp.1171-1178, 2024 (SCI-Expanded)
- XXVI. Adjuvant Concurrent Chemoradiotherapy (CRT) plus Docetaxel-Cisplatin-Fluorouracil (DCF) versus CRT plus Fluorouracil-Folinic Acid (FUFA) in Stage III Gastric Cancer**
Alkan A., Mizrak D., Yaşar A., Karci E., KÖKSOY E. B., Ürün M., Özyurt N., Kuştaş A. A., Kütük T., ÜRÜN Y., et al.
Journal of Cancer Research and Therapeutics, vol.20, no.3, pp.913-917, 2024 (SCI-Expanded)
- XXVII. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)**
Gillesen S., Turco F., Davis I. D., Efstathiou J. A., Fizazi K., James N. D., Shore N., Small E., Smith M., Sweeney C. J., et al.
European Urology, 2024 (SCI-Expanded)
- XXVIII. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis.**
BÖLEK H., Yekedüz E., ÜRÜN Y.
Cancer treatment reviews, vol.122, pp.102667, 2024 (SCI-Expanded)
- XXIX. Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer**
AKBIYIK I., ÜRÜN Y.
FUTURE ONCOLOGY, no.39, pp.2585-2591, 2023 (SCI-Expanded)

- XXX. **Adjuvant therapy for renal cell carcinoma: A systematic review of current landscape and future directions**
BÖLEK H., ÜRÜN Y.
Critical Reviews in Oncology/Hematology, vol.192, 2023 (SCI-Expanded)
- XXXI. **Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma**
van der Heijden M. S., Sonpavde G., Powles T., Necchi A., Burotto M., Schenker M., Sade J. P., Bamias A., Beuzeboc P., Bedke J., et al.
NEW ENGLAND JOURNAL OF MEDICINE, vol.389, pp.1778-1789, 2023 (SCI-Expanded)
- XXXII. **Cancer-associated thrombosis and drug-drug interactions of antithrombotic and antineoplastic agents**
BÖLEK H., ÜRÜN Y.
CANCER, vol.129, no.20, pp.3216-3229, 2023 (SCI-Expanded)
- XXXIII. **The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study**
Güven D. C., Yekedüz E., Erül E., YAZGAN S. C., Sahin T. K., KARATAŞ G., Aksoy S., Erman M., Yalcin S., Urun Y., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.149, no.7, pp.3599-3606, 2023 (SCI-Expanded)
- XXXIV. **Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer**
Yekedüz E., McKay R. R., Gillessen S., Choueiri T. K., ÜRÜN Y.
ONCOLOGIST, vol.28, no.7, pp.596-603, 2023 (SCI-Expanded)
- XXXV. **Patient preferences for use of archived biospecimens in Turkey**
Tolunay P. K., Erol C., Kahraman S., Tacar S. Y., Ozcan E., Basal F. B., Kose F., Sendur M. A. N., Tural D., Cicin I., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.41, no.16, 2023 (SCI-Expanded)
- XXXVI. **Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice**
Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Akar E., ERMAN M., ÜRÜN Y., Erdem D., Karadurmus N., Kilickap S.
Clinical Genitourinary Cancer, vol.21, no.3, pp.334-341, 2023 (SCI-Expanded)
- XXXVII. **Awareness and perceptions of clinical trials in patients with cancer and their families in Turkey**
Kubilay P., Erol C., Kahraman S., Tacar S. Y., Ozcan E., Basal F. B., Kose F., Sendur M. A. N., Tural D., Cicin I., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.41, no.16, 2023 (SCI-Expanded)
- XXXVIII. **Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022**
Gillessen S., Bossi A., Davis I. D., de Bono J., Fizazi K., James N. D., Mottet N., Shore N., Small E., Smith M., et al.
European Journal of Cancer, vol.185, pp.178-215, 2023 (SCI-Expanded)
- XXXIX. **Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022**
Gillessen S., Bossi A., Davis I. D., de Bono J., Fizazi K., James N. D., Mottet N., Shore N., Small E., Smith M., et al.
European Urology, vol.83, no.3, pp.267-293, 2023 (SCI-Expanded)
- XL. **External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.**
Yekedüz E., Karakaya S., Ertürk İ., Tural D., Uçar G., Şentürk Öztaş N., Arıkan R., Hızal M., Küçükarda A., Sever Ö. N., et al.
Clinical genitourinary cancer, vol.21, no.1, pp.175-182, 2023 (SCI-Expanded)
- XLI. **Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA**
Matsubara N., de Bono J., Olmos D., Procopio G., Kawakami S., ÜRÜN Y., van Alphen R., Flechon A., Carducci M. A., Choi Y. D., et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, vol.29, no.1, pp.92-99, 2023 (SCI-Expanded)

- XLII. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium.**
Erol C., Yekedüz E., Tural D., Karakaya S., Şentürk Öztaş N., Uçar G., Kılıçkap S., Ertürk İ., Sever Ö. N., Arslan Ç., et al.
Urologia internationalis, vol.107, no.6, pp.595-601, 2023 (SCI-Expanded)
- XLIII. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study**
Yekeduz E., Tural D., Erturk I., Karakaya S., EROL C., Ercelep O., Arslan C., Sever O. N., KILIÇKAP S., Senturk Oztas N., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.148, no.12, pp.3537-3546, 2022 (SCI-Expanded)
- XLIV. Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors**
YAZGAN S. C., Yekeduz E., UTKAN G., ÜRÜN Y.
PROSTATE, vol.82, no.15, pp.1456-1461, 2022 (SCI-Expanded)
- XLV. Chronic hyperglycemia based on diabetes is independently associated with decreased survival in patients with advanced cancer treated with immune checkpoint inhibitors**
Yekeduz E., KÖKSOY E. B., YAZGAN S. C., KARATAŞ G., ÇAY ŞENLER F., UTKAN G., AKBULUT H., DEMİRKAZIK A., ÜRÜN Y.
ANTI-CANCER DRUGS, vol.33, no.10, pp.1145-1149, 2022 (SCI-Expanded)
- XLVI. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors**
Yucel K. B., Yekeduz E., Karakaya S., Tural D., Erturk I., EROL C., Ercelep O., ŞENTÜRK ÖZTAŞ N., Arslan C., Ucar G., et al.
SCIENTIFIC REPORTS, vol.12, no.1, 2022 (SCI-Expanded)
- XLVII. Significance of metabolic tumor volume and total lesion uptake measured using Ga-68 labelled prostate-specific membrane antigen PET/CT in primary staging of prostate cancer**
KUBİLAY E., Akpınar Ç., OĞUZ E. S., ARAZ M., SOYDAL Ç., BALTACI S., ÜRÜN Y., SÜER E.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, vol.40, no.9, 2022 (SCI-Expanded)
- XLVIII. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study**
DOĞAN İ., Ayhan M., Gurbuz M., Kucukarda A., Aydın E., ÜRÜN Y., ÇİÇİN İ., Saip P.
MEDICINE, vol.101, no.35, 2022 (SCI-Expanded)
- XLIX. The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib**
Yekeduz E., Aktas E. G., KÖKSOY E. B., Dogan N., ÜRÜN Y., UTKAN G.
FUTURE ONCOLOGY, vol.18, pp.1067-1076, 2022 (SCI-Expanded)
- L. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study**
Yekeduz E., Ozbay M. F., Caglayan D., Yildirim A., Erol C., Yildirim H. C., Tunc S., Ozyurt N., Ozdemir F., Sendur M. A. N., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.4, 2022 (SCI-Expanded)
- LI. Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.**
Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Erman M., Urun Y., Karadurmus N., Akar E., Kilickap S.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.6, 2022 (SCI-Expanded)
- LII. Key considerations and common adverse events for HIV-positive patients with cancer treated with immune checkpoint inhibitors**
Yekeduz E., UTKAN G., ÜRÜN Y.
FUTURE ONCOLOGY, vol.18, pp.413-416, 2022 (SCI-Expanded)
- LIII. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer**

Aydin S. G., Demirel B. C., Bilici A., Topcu A., Aykan M. B., Kahraman S., Akbiyik I., Atci M. M., Olmez O. F., Yaren A., et al.

CURRENT MEDICAL RESEARCH AND OPINION, vol.38, no.10, pp.1751-1758, 2022 (SCI-Expanded)

- LIV. **Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database**
Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., Arikan R., Arslan C., Taban H., Kucukarda A., et al.
FUTURE ONCOLOGY, vol.17, pp.4861-4869, 2021 (SCI-Expanded)
- LV. **The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study.**
Güven D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., Ceylan F., Sendur M. A., Demirci U., ÜRÜN Y., et al.
Current problems in cancer, vol.45, no.6, pp.100760, 2021 (SCI-Expanded)
- LVI. **Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors**
Yekeduz E., Trapani D., Xu W., de Vries E. G. E., Labaki C., Gyawali B., Gulati S., Nabhan C., UTKAN G., Curigliano G., et al.
INTERNATIONAL JOURNAL OF CANCER, vol.149, no.7, pp.1455-1462, 2021 (SCI-Expanded)
- LVII. **Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation**
Erturk I., Karadurmus N., Kiziloz H., Acar R., Yildiz B., Aykan M. B., Esen R., Buyukturan G., ÜRÜN Y., Erdem G., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.7, pp.1657-1664, 2021 (SCI-Expanded)
- LVIII. **Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis**
Bakouny Z., Yekeduz E., Braun D. A., Berchuck J. E., Hirsch L., UTKAN G., Lee Y., Trinh Q., Choueiri T. K., ÜRÜN Y.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.166, 2021 (SCI-Expanded)
- LIX. **Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥ 75) patients**
Alkan A., Güc Z. G., Gurbuz M., ozgun G., Degirmencioglu S., Dogan M., Telli T. A., KESKİN Ö., Arslan C., Bilgin B., et al.
JOURNAL OF MENS HEALTH, vol.17, no.4, pp.128-134, 2021 (SCI-Expanded)
- LX. **Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer**
Soydal Ç., Araz M., Ürün Y., Nak D., Özkan E., Küçük N. Ö.
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.65, no.3, pp.282-286, 2021 (SCI-Expanded)
- LXI. **Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences**
Tural D., Ölmez Ö. F., Sümbül A. T., Artaç M., Özhan N., Akar E., ÇAKAR B., Köstek O., EKENEL M., ERMAN M., et al.
European Urology Focus, vol.7, no.5, pp.1061-1066, 2021 (SCI-Expanded)
- LXII. **mRNA-based COVID-19 vaccines appear not to increase immune events in cancer patients receiving immune checkpoint inhibitors**
Yekeduz E., Ayasun R., KÖKSOY E. B., UTKAN G., ÜRÜN Y., AKBULUT H.
FUTURE VIROLOGY, vol.16, no.9, pp.583-585, 2021 (SCI-Expanded)
- LXIII. **Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab**
Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., Ekenel M., ERMAN M., COŞKUN H. Ş., Selcukbiricik F., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.8, pp.1506-1513, 2021 (SCI-Expanded)
- LXIV. **Response to letter entitled: Re: A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19**
Yekeduz E., UTKAN G., ÜRÜN Y.

- EUROPEAN JOURNAL OF CANCER, vol.152, pp.248-249, 2021 (SCI-Expanded)
- LXV. **In the Age of Immunotherapy, How Can We Translate the CARMENA Results into Practice?**
Yekeduz E., SÜER E., UTKAN G., BALTACI S., ÜRÜN Y.
EUROPEAN UROLOGY ONCOLOGY, vol.4, no.3, pp.515-516, 2021 (SCI-Expanded)
- LXVI. **Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?**
Yekeduz E., UTKAN G., Kanesvaran R., ÜRÜN Y.
PROSTATE INTERNATIONAL, vol.9, no.1, pp.1-5, 2021 (SCI-Expanded)
- LXVII. **Commentary: Should all cancer patients be tested for COVID-19 before each chemotherapy cycle?**
Yekeduz E., UTKAN G., ÜRÜN Y.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.2, pp.450-452, 2021 (SCI-Expanded)
- LXVIII. **Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.**
Matsubara N., De Bono J. S., Olmos D., Procopio G., Kawakami S., ÜRÜN Y., van Alphen R. J., Flechon A., Carducci M. A., Choi Y. D., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.6, 2021 (SCI-Expanded)
- LXIX. **Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.**
Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., Arslan C., Taban H., Kucukarda A., ŞENTÜRK ÖZTAŞ N., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.6, 2021 (SCI-Expanded)
- LXX. **A retrospective multicenter study: Clinicopathological factors affecting recurrence-free survival in operable gastric cancer patients.**
Yekeduz E., Dogan I., AKBULUT H., Karabulut S., UTKAN G., ÜRÜN Y.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.3, 2021 (SCI-Expanded)
- LXXI. **ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis**
Yekeduz E., KÖKSOY E. B., AKBULUT H., ÜRÜN Y., UTKAN G.
FUTURE ONCOLOGY, vol.17, no.03, pp.349-357, 2021 (SCI-Expanded)
- LXXII. **A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19**
Yekeduz E., Utkan G., ÜRÜN Y.
EUROPEAN JOURNAL OF CANCER, vol.141, pp.92-104, 2020 (SCI-Expanded)
- LXXIII. **Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer**
Kenar G., KÖKSOY E. B., ÜRÜN Y., UTKAN G.
SUPPORTIVE CARE IN CANCER, vol.28, no.11, pp.5235-5242, 2020 (SCI-Expanded)
- LXXIV. **Sweet's syndrome under ipilimumab therapy and a brief comparison of the cases in literature**
Yasar H. A., AKKUŞ E., HEPER A., Akay B. N., ÜRÜN Y., UTKAN G.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.7, pp.1762-1764, 2020 (SCI-Expanded)
- LXXV. **Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)**
Hizal M., ŞENDUR M. A. N., Yasar H. A., Bir Yucel K., Arslan C., Ucar G., Karakaya S., Taban H., Kucukarda A., Erturk I., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.7, pp.1583-1589, 2020 (SCI-Expanded)
- LXXVI. **A clinical dilemma amid COVID-19 pandemic: missed or encountered diagnosis of cancer?**
Yekeduz E., Karcioğlu A. M., UTKAN G., ÜRÜN Y.
FUTURE ONCOLOGY, vol.16, no.25, pp.1879-1881, 2020 (SCI-Expanded)
- LXXVII. **Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab**
Yekeduz E., DURSUN B., Aydin G., YAZGAN S. C., Ozturks H. H., AZAP A., UTKAN G., ÜRÜN Y.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, no.5, pp.1289-1294, 2020 (SCI-Expanded)
- LXXVIII. **The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer**

- Yasar H. A., Yucel K. B., Arslan C., Ucar G., Karakaya S., Bilgin B., Taban H., Kucukarda A., Erturk I., Hizal M., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.5, pp.1110-1116, 2020 (SCI-Expanded)
- LXXXIX. **A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma**
Yekeduz E., Arzu Yasar H. A., UTKAN G., ÜRÜN Y.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.4, pp.972-981, 2020 (SCI-Expanded)
- LXXX. **Predictor of Ga-68 PSMA PET/CT positivity in patients with prostate cancer**
Soydal Ç., Ürün Y., Süer E., Nak D., Özkan E., Küçük N. Ö.
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.64, no.2, pp.226-230, 2020 (SCI-Expanded)
- LXXXI. **Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study**
Yildiz B., Kucukarda A., Gokyer A., Demiray A. G., PAYDAŞ S., Aral I. P., GÜMÜŞAY Ö., Bilici A., Akdeniz N., Bahceci A., et al.
JOURNAL OF BUON, vol.25, no.2, pp.1130-1135, 2020 (SCI-Expanded)
- LXXXII. **Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study**
Yasar H. A., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., Ozdemir N., ŞENDUR M. A. N., Sezer A., KILIÇKAP S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.2, pp.267-272, 2020 (SCI-Expanded)
- LXXXIII. **Onco-cardiology: Drug-drug interactions of antineoplastic and cardiovascular drugs**
Akbulut M., ÜRÜN Y.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.145, 2020 (SCI-Expanded)
- LXXXIV. **Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?**
ÜRÜN Y., Yasar H. A., TURNA Z. H., KILIÇKAP S., Sezer A., Oksuzoglu B., ÖZDEMİR N., ŞENDUR M. A. N., Abali H.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.25, no.8, pp.2062-2063, 2019 (SCI-Expanded)
- LXXXV. **Comparison of bone scintigraphy and Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography in the detection of bone metastases of prostate carcinoma**
Soydal Ç., Nak D., Araz M., Akkus P., Ürün Y., Özkan E., Küçük N. Ö., Kır K. M.
NUCLEAR MEDICINE COMMUNICATIONS, vol.40, no.12, pp.1243-1249, 2019 (SCI-Expanded)
- LXXXVI. **F-18-Fluorodeoxy glucose PET-computed tomography in testicular carcinoma: diagnostic and prognostic value**
Soydal Ç., Araz M., Ürün Y., Gülpınar B., Nak D., Özkan E., Küçük N. Ö.
NUCLEAR MEDICINE COMMUNICATIONS, vol.40, no.12, pp.1268-1274, 2019 (SCI-Expanded)
- LXXXVII. **Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study**
ÜRÜN Y., Yasar H. A., TURNA Z. H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., Ozdemir N., ŞENDUR M. A. N., Sezer A., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.25, no.7, pp.1658-1664, 2019 (SCI-Expanded)
- LXXXVIII. **Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes**
Esin E., Oksuzoglu B., Bilici A., Cicin I., Kostek O., Kaplan M. A., AKSOY S., AKTAŞ B. Y., Ozdemir O., Alacacioglu A., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.1, pp.131-143, 2019 (SCI-Expanded)
- LXXXIX. **Merkel cell carcinoma in Turkey: A multicentric study.**
Yildiz F., BÜYÜKŞİMŞEK M., Sakalar T., AYDIN ÜLGEN Ö., TURNA Z. H., Babacan N. A., Yildiz B., Arslan C., Ozdemir N., ÜRÜN Y., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XC. **Independent prognostic value of inflammation in metastatic pancreatic cancer.**
Oksuzoglu B., Esin E., Koksoy E. B., Demirci N. S., Sendur M. A. N., Dede I., Sezer A., Karci E., Yildirim N., Yalcin B., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)

- XCI. Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: a retrospective analysis**
Ergun Y., Ozdemir N. Y., Guner E. K., Esin E., ŞENDUR M. A. N., KÖKSOY E. B., Demirci N. S., Eren T., Dede I., Sezer A., et al.
JOURNAL OF BUON, vol.23, 2018 (SCI-Expanded)
- XCII. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis**
ÜRÜN Y., Leow J. J., Fay A. P., Albiges L., Choueiri T. K., Bellmunt J.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.120, pp.120-126, 2017 (SCI-Expanded)
- XCIII. Relationship between metabolic parameters and ras mutation status**
Karci E., SOYDAL Ç., Utkan G., ÜRÜN Y., Akbulut H.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.44, 2017 (SCI-Expanded)
- XCIV. Vaccination in oncology practice and predictors**
Alkan A., Karci E., Yasar A., Tuncay G., KÖKSOY E. B., Urun M., ÇAY ŞENLER F., DEMİRKAZIK A., UTKAN G., AKBULUT H., et al.
SUPPORTIVE CARE IN CANCER, vol.25, no.9, pp.2677-2682, 2017 (SCI-Expanded)
- XCv. Benign metastasizing leiomyoma of bone and lung in postmenopausal women: two rare case reports and review of the literature**
Cirak Y., Sever O. N., ÜRÜN Y.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.38, no.1, pp.118-121, 2017 (SCI-Expanded)
- XCVI. Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients**
Alkan A., Yasar A., Karci E., KÖKSOY E. B., Urun M., ÇAY ŞENLER F., ÜRÜN Y., Tuncay G., ERGÜN H., AKBULUT H.
SUPPORTIVE CARE IN CANCER, vol.25, no.1, pp.229-236, 2017 (SCI-Expanded)
- XCvII. Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma**
de Velasco G., Gray K. P., Hamieh L., ÜRÜN Y., Carol H. A., Fay A. P., Signoretti S., Kwiatkowski D. J., McDermott D. F., Freedman M., et al.
EUROPEAN UROLOGY FOCUS, vol.2, no.6, pp.633-639, 2016 (SCI-Expanded)
- XCvIII. Breast cancer survivors suffer from persistent postmastectomy pain syndrome and posttraumatic stress disorder (ORTHUS study): a study of the palliative care working committee of the Turkish Oncology Group (TOG)**
Alkan A., Guc Z. G., ÇAY ŞENLER F., YAVUZŞEN T., Onur H., Dogan M., Karci E., Yasar A., KÖKSOY E. B., TANRIVERDİ Ö., et al.
SUPPORTIVE CARE IN CANCER, vol.24, no.9, pp.3747-3755, 2016 (SCI-Expanded)
- XCIX. ABO Blood Group Alleles and Prostate Cancer Risk: Results from the Breast and Prostate Cancer Cohort Consortium (BPC3)**
Markt S. C., Shui I. M., Unger R. H., ÜRÜN Y., Berg C. D., Black A., Brennan P., Bueno-de-Mesquita H. B., Gapstur S. M., Giovannucci E., et al.
PROSTATE, vol.75, no.15, pp.1677-1681, 2015 (SCI-Expanded)
- C. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer**
ÜRÜN Y., UTKAN G., Yalcin B., AKBULUT H., Onur H., Oztuna D., Şenler F., DEMİRKAZIK A., İçli F.
Experimental Oncology, vol.37, no.1, pp.53-57, 2015 (SCI-Expanded)
- CI. Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials**
Leow J. J., Martin-Doyle W., Rajagopal P. S., Patel C. G., Anderson E. M., Rothman A. T., Cote R. J., ÜRÜN Y., Chang S. L., Choueiri T. K., et al.
EUROPEAN UROLOGY, vol.66, no.1, pp.42-54, 2014 (SCI-Expanded)
- CII. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC)**
Aizer A. A., ÜRÜN Y., McKay R. R., Kibel A. S., Nguyen P. L., Choueiri T. K.
BJU INTERNATIONAL, vol.113, no.5B, 2014 (SCI-Expanded)

- CIII. **Predictors of Outcome in Patients with Advanced Nonseminomatous Germ Cell Testicular Tumors**
Yetisyigit T., Babacan N., ÜRÜN Y., Seber E. S., Cihan S., Arpacı E., Yildirim N., Aksoy S., Budakoglu B., Zengin N., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.2, pp.831-835, 2014 (SCI-Expanded)
- CIV. **Cetuximab Related Eyelash Elongations for Patients with Metastatic Rectum Carcinoma: Metabolic Complete Response**
ÜRÜN Y., UTKAN G.
ANNALS OF DERMATOLOGY, vol.25, no.4, pp.504-505, 2013 (SCI-Expanded)
- CV. **Perception about influenza and pneumococcal vaccines and vaccination coverage among patients with malignancies and their family members**
ÜRÜN Y., AKBULUT H., DEMİRKAZIK A., Senler F. C., Utkan G., Onur H., Icli F.
JOURNAL OF BUON, vol.18, no.2, pp.511-515, 2013 (SCI-Expanded)
- CVI. **Intraabdominal follicular dendritic cell sarcoma: A report of three cases and review of the literature**
ÜRÜN Y., Kankaya D., Koral L., YALÇIN B., Karabork A., CEYHAN K., Boruban M. C., UTKAN G., DEMİRKAZIK A.
Tumori, vol.99, no.2, 2013 (SCI-Expanded)
- CVII. **Clinicopathological Features of Patients with Malignant Mesothelioma in a Multicenter, Case-Control Study: No Role for ABO-Rh Blood Groups**
UTKAN G., ÜRÜN Y., KAYI CANGIR A., Kilic D., Ozdemir N. Y., Oztuna D., Bulut E., Arslan U. Y., Kocer M., Kavukcu S., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, no.1, pp.249-253, 2013 (SCI-Expanded)
- CVIII. **Association of ABO Blood Group and Risk of Lung Cancer in a Multicenter Study in Turkey**
ÜRÜN Y., UTKAN G., KAYI CANGIR A., Oksuzoglu O. B., Ozdemir N., Oztuna D., KOCAMAN G., COŞKUN H. Ş., Kaplan M. A., YÜKSEL C., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, no.5, pp.2801-2803, 2013 (SCI-Expanded)
- CIX. **Isolated Pulmonary Metastasis Presenting with an CEA Elevation Five Years After Radical Prostatectomy**
ÜRÜN Y., UTKAN G., Percinel S., KAYI CANGIR A., Dogani M., Icli F.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.23, no.3, pp.200-201, 2013 (SCI-Expanded)
- CX. **Rituximab-related cryptogenic organizing pneumonia and late onset neutropenia in a patient with non-Hodgkin lymphoma: Report of two rare complications and review of the literature**
ÜRÜN Y., Dincol D., ÖZDEMİR KUMBASAR Ö.
JOURNAL OF BUON, vol.17, no.3, pp.602-603, 2012 (SCI-Expanded)
- CXI. **Solid pseudopapillary tumor of the pancreas: A case series of 7 patients**
ÜRÜN Y., Kepenekci I., Tuzuner A., Dogan M., Erden E., Utkan G., Icli F.
Journal of B.U.ON., vol.17, no.3, pp.600-601, 2012 (SCI-Expanded)
- CXII. **ABO and Rh blood groups frequency in women with HER2 positive breast cancer**
ÜRÜN Y., Utkan G., Altundag K., Arslan O., Onur H., Arslan U. Y., Kocer M., DOĞAN İ., Senler F. C., Yalcin B., et al.
JOURNAL OF BUON, vol.17, no.3, pp.457-460, 2012 (SCI-Expanded)
- CXIII. **Primary extranodal non-Hodgkin's lymphoma presenting as painful gingival swelling**
ÜRÜN Y., Can F., BARIŞ E., AKBULUT H., UTKAN G., Icli F.
Experimental Oncology, vol.34, no.2, pp.134-135, 2012 (SCI-Expanded)
- CXIV. **Lack of Any Relationship between ABO and Rh Blood Groups and Clinicopathological Features in Patients with Gastrointestinal Stromal Tumors: Turkish Oncology Group**
ÜRÜN Y., Utkan G., YALÇIN Ş., COŞKUN H. Ş., Kocer M., Ozdemir N. Y., Kaplan M. A., Arslan U. Y., ÖZDEMİR F., Oztuna D., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, no.8, pp.4129-4131, 2012 (SCI-Expanded)
- CXV. **ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma**
ÜRÜN Y., Ozdemir N. Y., UTKAN G., AKBULUT H., SAVAŞ B., Oksuzoglu B., Oztuna D., DOĞAN İ., YALÇIN B., ÇAY ŞENLER F., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, no.12, pp.6097-6100, 2012 (SCI-Expanded)
- CXVI. **Kikuchi - Fujimoto disease: Cervical lymphadenopathy suggestive of relapsing lymphoma in patient with lymphoblastic lymphoma**

- ÜRÜN Y., UTKAN G., Kankaya D., DOĞAN M. K., YALÇIN B., Icli F.
Experimental Oncology, vol.33, no.4, pp.242-244, 2011 (SCI-Expanded)
- CXVII. **Angiosarcoma related to immunosuppressive therapy 8 years after renal transplantation**
ÜRÜN Y., DOĞAN İ., KİREMİTÇİ S., AKBULUT H., Icli F.
ANNALS OF TRANSPLANTATION, vol.16, no.4, pp.138-140, 2011 (SCI-Expanded)
- CXVIII. **Two cases with atypical metastasis in colorectal cancer: Splenic and renal metastasis**
DOĞAN M. K., Ozal G., Ekinci C., UTKAN G., ÜRÜN Y., Yalcin B., Icli F.
Experimental Oncology, vol.32, no.4, pp.277-279, 2010 (SCI-Expanded)
- CXIX. **How Shall We Name the Chemotherapy Administration Before and After Metastasectomy? How About "M-Neoadjuvant" and "M-Adjuvant"?**
Abali H., Disel U., ÜRÜN Y., Gullu I., Saif M. W.
ANNALS OF SURGICAL ONCOLOGY, vol.17, no.7, pp.1970, 2010 (SCI-Expanded)
- CXX. **Silent Celiac Disease Presenting With PolyarthritiS**
Efe C., ÜRÜN Y., Purnak T., Ozaslan E., Ozbalkan Z., SAVAŞ B.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, vol.16, no.4, pp.195-196, 2010 (SCI-Expanded)
- CXXI. **Activity of pemetrexed on brain metastases from non-small cell lung cancer: What is the mechanism?**
Dogan M., Yalcin B., UTKAN G., ÜRÜN Y., Ozal G.
LUNG CANCER, vol.66, no.3, pp.399, 2009 (SCI-Expanded)
- CXXII. **Two cases with horseshoe kidney in association with nephrotic syndrome: Is there a causal relationship between two conditions?**
Kayatas M., ÜRÜN Y.
RENAL FAILURE, vol.29, no.4, pp.517-518, 2007 (SCI-Expanded)
- CXXIII. **Performing only one cardiovascular reflex test has a high positive predictive value for diagnosing autonomic neuropathy in patients with chronic renal failure on hemodialysis**
Sahin M., Kayatas M., ÜRÜN Y., Sennaroglu E., Akdur S.
RENAL FAILURE, vol.28, no.5, pp.383-387, 2006 (SCI-Expanded)
- CXXIV. **Reversible edema in a male patient taking parenteral pantoprazole infusion for pyloric stenosis**
Sennaroglu E., Karakan S., Kayatas M., Akdur S., Genc H., Karakan T., Ucler R., Ozisler C., ÜRÜN Y.
DIGESTIVE DISEASES AND SCIENCES, vol.51, no.1, pp.121-122, 2006 (SCI-Expanded)
- CXXV. **Bradycardia due to methylprednisolone therapy**
Beyan E., ÜRÜN Y., Uzuner A.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, vol.10, no.4, pp.230, 2004 (SCI-Expanded)

Articles Published in Other Journals

- I. **Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study**
AYDIN S., Kavak E. E., Topcu A., BAYRAMGİL A., Akgul F., Kahraman S., Aykan M. B., Altıntaş Y. E., Helvacı K., ÜRÜN Y., et al.
Biomolecules and Biomedicine, vol.23, no.6, pp.1089-1095, 2023 (Scopus)
- II. **Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience**
Erol C., Bardakçı M., Hizal M., Kahraman S., Yekedüz E., Güven D. C., Aykan M. B., Ak R., Ateş Ö., ŞENER DEDE D., et al.
Journal of Oncological Science, vol.9, no.2, pp.72-78, 2023 (Scopus)
- III. **Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study**
Yekeduz E., DOĞAN İ., Kaya D. M., ÖZGÜR İ., UTKAN G., VATANSEVER S., DEMİRCİ S., AKBULUT H., ÜRÜN Y.
JOURNAL OF GASTROINTESTINAL CANCER, vol.53, no.4, pp.870-879, 2022 (ESCI)
- IV. **Predictive Factor for Lymph Node Metastasis in Non-Metastatic Colorectal Adenocarcinomas**
Karcı E., Ürün Y., Köksoy E. B., Yekedüz E., Utkan G., Akbulut H., Uçar G., Bilgin B., Arslan Ç., Alkan A., et al.

Eurasian Journal of Medical Investigation, vol.6, no.3, pp.279-283, 2022 (Peer-Reviewed Journal)

- V. **Management of metastatic castration-resistant prostate cancer in Middle East African countries: Challenges and strategic recommendations**
Bazarbashi S., Alsharm A., Meshref A., Mrabti H., Ansari J., Ghosn M., Abdulla M., Urun Y.
UROLOGY ANNALS, vol.14, no.4, pp.303-313, 2022 (ESCI)
- VI. **Genomic Landscape of Actionable Mutations in Primary and Metastatic Tissues of Colon Adenocarcinoma**
Yekeduz E., AKBULUT H., UTKAN G., ÜRÜN Y.
CUREUS JOURNAL OF MEDICAL SCIENCE, vol.14, no.4, 2022 (ESCI)
- VII. **Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience**
Yekedüz E., Köksoy E. B., Şenler F., Akbulut H., Demirkazık A., Ürün Y., Utkan G.
Ankara Üniversitesi Tıp Fakültesi Mecmuası, vol.75, no.1, pp.103-106, 2022 (Peer-Reviewed Journal)
- VIII. **Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A Real-life Experience from a Multicenter Retrospective Cohort Study.**
YEKEDÜZ E., DOĞAN İ., DURU BİRGİ S., KESKİN M., KARAMAN Ş., UTKAN G., KARABULUT S., BAYAR S., AKBULUT H., DEMİRCİ S., et al.
Euroasian journal of hepato-gastroenterology, vol.11, no.2, pp.51-58, 2021 (Peer-Reviewed Journal)
- IX. **Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study**
Selvi I., Guven E. O., KÜTÜKOĞLU M. U., ÜRÜN Y., Tinay I.
UROONKOLOJİ BULTENİ-BULLETIN OF UROONCOLOGY, vol.20, no.2, pp.96-106, 2021 (ESCI)
- X. **Changes in Metastatic Castration Sensitive Prostate Cancer**
Gurbuz M., ÜRÜN Y.
UROONKOLOJİ BULTENİ-BULLETIN OF UROONCOLOGY, vol.20, no.1, pp.1-6, 2021 (ESCI)
- XI. **Seasonal influenza and pneumococcal vaccination rates among patients with cancer in covid-19 pandemic: A cross-sectional study**
Yekedüz E., KÖKSOY E. B., YAZGAN S. C., AKBİYİK İ., BALLI S., Kavak E. E., KALACI E., DURSUN B., Kubilay Tolunay P., Gürbüz M., et al.
Journal of Oncological Science, vol.7, no.2, pp.64-70, 2021 (Scopus)
- XII. **Association between blood type and epidermal growth factor receptor mutation positivity in lung adenocarcinoma patients**
Gürbüz M., AKKUŞ E., Karaaliğlu B., Aktaş E. G., KÖKSOY E. B., ÖZAKINCI H., Hayme S., ÜRÜN Y., SAK S., DEMİRKAZIK A., et al.
Journal of Oncological Science, vol.7, no.1, pp.20-24, 2021 (Scopus)
- XIII. **Efficacy of Chemotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer Patients - Do Homologous Recombination Deficiency Affect the Outcomes?**
Yekeduz E., UTKAN G., ÜRÜN Y.
UROONKOLOJİ BULTENİ-BULLETIN OF UROONCOLOGY, vol.19, no.4, pp.175-176, 2020 (ESCI)
- XIV. **Oncologic approaches for bone metastasis related pain Ağrılı Kemik Metastazlarında Onkolojik Yaklaşımlar**
YEKEDÜZ E., UTKAN G., ÜRÜN Y.
Nuclear Medicine Seminars, vol.6, no.1, pp.11-16, 2020 (Scopus)
- XV. **The Impact of Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients**
ALKAN A., ÜRÜN Y., UTKAN G., AKBULUT H., TUNCAY G., ARAS S., VARLI M.
Journal of Oncological Sciences, vol.6, no.2, pp.65-70, 2020 (Peer-Reviewed Journal)
- XVI. **The Impact of Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients.**
ALKAN A., ÖZTORUN H. S., KARCI E., ÜRÜN Y., TUNCAY G., YAŞAR H. A., ÇINAR E., ARAS S., VARLI M., UTKAN G., et al.
Journal of Oncological Sciences, vol.6, no.2, pp.65-70, 2020 (Peer-Reviewed Journal)
- XVII. **Nuclear Medicine Applications in Diagnosis of Urological Tumors**
Araz M., Ürün Y.

- UROONKOLOJİ BULTENİ-BULLETIN OF UROONCOLOGY, vol.18, no.2, pp.80-88, 2019 (ESCI)
- XVIII. **Targeted Agents and Resistance Mechanism in Renal Cell Cancer**
Rezapourbehnagh S., Yasar H. A., Arslan C., ÜRÜN Y.
UROONKOLOJİ BULTENİ-BULLETIN OF UROONCOLOGY, vol.18, no.2, pp.73-79, 2019 (ESCI)
- XIX. **Risk factors for thrombosis risk in patients with cancer**
TURAN D., YAŞAR H. A., Aksu O. B., KÖKSOY E. B., UTKAN G., AKBULUT H., ÜRÜN Y.
Journal of Oncological Sciences, vol.4, no.3, pp.130-133, 2018 (Peer-Reviewed Journal)
- XX. **Osteonecrosis of the jaw with sunitinib and zoledronic acid combination: A case report**
Tolunay P. K., YAŞAR H. A., UTKAN G., ÜRÜN Y.
Journal of Oncological Sciences, vol.4, no.2, pp.116-118, 2018 (Peer-Reviewed Journal)
- XXI. **Positron Emission Tomography in Renal Cell Carcinoma**
SOYDAL Ç., ÜRÜN Y.
UROONKOLOJİ BULTENİ-BULLETIN OF UROONCOLOGY, vol.17, no.2, pp.68-72, 2018 (ESCI)
- XXII. **Place in Concomitant Use with Anti-EGFR Radiotherapy in Locally Advanced Head and Neck Cancer Treatment**
DAĞDELEN M., ÜRÜN Y.
MEANDROS MEDICAL AND DENTAL JOURNAL, vol.19, no.1, pp.95-98, 2018 (ESCI)
- XXIII. **Retrospective analysis of patients with relapsed or refractory germ cell tumors treated with autologous hematopoietic stem cell transplantation**
Ertürk I., Yildiz B., Karadurmuş N., Tosun B., Esen R., Sürmeli Z. G., Başgöz B., Özaydin Ş., Hançerlioğulları O., ÜRÜN Y., et al.
Gulhane Medical Journal, vol.60, no.4, pp.130-135, 2018 (Scopus)

Books & Book Chapters

- I. **Mesane Ve Böbrek Kanseri**
YAŞAR H. A., ÜRÜN Y.
in: Geriatrik Onkoloji, Karaoğlu Aziz, Yavuzşen Tuğba, Editor, Nobel Tıp Kitapevi, pp.279-288, 2021
- II. **Spinal Cord Compression**
KÖKSOY E. B., ÜRÜN Y.
in: ESMO HANDBOOK OF ONCOLOGICAL EMERGENCIES, Mariano Provencio Pulla, Editor, ESMO Press, Rickmansworth, Hertfordshire, pp.71-76, 2016

Refereed Congress / Symposium Publications in Proceedings

- I. **Lutesyum-177 (177Lu)-PSMA-617 ile tedavi edilen metastatik kastrasyon dirençli prostat kanseri hastalarında Pan-İmmün inflamasyon değerinin prognostik Rolü**
YAZGAN S. C., YEKEDÜZ E., ARAZ M., BÖLEK H., KÜÇÜK N. Ö., ÜRÜN Y.
On TARGED Master Oncology, 26 - 29 October 2024
- II. **Dual FES/FDG PET/CT imaging to predict therapy response in patients with estrogen receptor-positive recurrent or metastatic breast cancer: Preliminary Results**
DURŞUN E., ÖZKAN E., YAŞAR H. A., ARAZ M., AKSOY S., ÜRÜN Y., KÜÇÜK N. Ö.
Annuals Congress of the European Association of Nuclear Medicine, 19 - 23 October 2024, vol.51, pp.493-494
- III. **Metastatik Prostat Kanserinde Yüksek Volümlü Kemik Metastazının Yapay Zeka ile Tahmin Edilebilirliğinin Araştırılması**
ERDAT E. C., YAZGAN S. C., YEKEDÜZ E., ÜRÜN Y.
On-Targed Master Oncology, Muğla, Turkey, 26 - 29 September 2024
- IV. **Biyokimyasal nüks izlenen prostat Ca hastalarında F-18 PSMA PET/BT'nin başarısının değerlendirilmesi.**

SÜTÇÜ G., SOYDAL Ç., ARAZ M., ÜRÜN Y., SÜER E., BALTACI S., KÜÇÜK N. Ö.

36.Ulusal Nükleer Tıp Kongresi, 8 - 12 May 2024

- V. **Lu-177 PSMA tedavisine yanıtın RECIP kriterleri ve PSA düzeyi ile değerlendirilmesi ve sağkalım ile korelasyonu**
ÖZKAN E., DEMİR B., SOYDAL Ç., DURSUN E., ARAZ M., ÜRÜN Y., KÜÇÜK N. Ö.
36.Ulusal Nükleer Tıp Kongresi, 8 - 12 May 2024
- VI. **Evaluation of the success of 18F-PSMA PET/CT in the detection of prostate cancer recurrence in patients with biochemical recurrence**
SÜTÇÜ G., SOYDAL Ç., ARAZ M., ÜRÜN Y., SÜER E., BALTACI S., KÜÇÜK N. Ö.
Annual Congress of European Association of Nuclear Medicine, 9 - 13 September 2023
- VII. **Evaluation of the success of 18F-PSMA PET/CT in the detection of prostate cancer recurrence in patients with biochemical recurrence**
SÜTÇÜ G., SOYDAL Ç., ARAZ M., ÜRÜN Y., SÜER E., BALTACI S., KÜÇÜK N. Ö.
Annuals Congress of the European Association of Nuclear Medicine, 9 - 13 September 2023
- VIII. **Pre-treatment 68Ga-PSMA PET/CT parameters could predict response to 177Lu-PSMA treatment and overall survival in metastatic castration resistant prostate carcinoma patients treated with 177Lu-PSMA**
ÖZKAN E., DEMİR B., ÖZTÜRK M., ARAZ M., SOYDAL Ç., DURSUN B., ÜRÜN Y., KÜÇÜK N. Ö.
Annuals Congress of the European Association of Nuclear Medicine, 9 - 13 September 2023
- IX. **Pre-treatment 68Ga-PSMA PET/CT parameters could predict response to 177Lu-PSMA treatment and overall survival in metastatic castration resistant prostate carcinoma patients treated with 177Lu-PSMA**
ÖZKAN E., DEMİR B., ÖZTÜRK M., ARAZ M., SOYDAL Ç., DURSUN B., ÜRÜN Y., KÜÇÜK N. Ö.
Annuals Congress of the European Association of Nuclear Medicine, 9 - 13 September 2023
- X. **Comparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma.**
Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Akar E., Erman M., Urun Y., Erdem D., Kilickap S.
Genitourinary Cancers Symposium, ELECTR NETWORK, 16 - 18 February 2023
- XI. **Comparison of genomic landscape in young and older patients with metastatic renal cell carcinoma: Results from the AACR project GENIE**
YEKEDÜZ E., ÜRÜN Y.
4. Uluslararası 15. Akademik Geriatri Kongresi, Turkey, 14 - 18 September 2022, pp.160-161
- XII. **İleri evre malignitelerde immüncheckpoint inhibitörleri ile eş zamanlı verilen antihistaminiklerin sağkalım katkısı ile ilgili gerçek yaşam verileri**
EYLEMER MOCAN E., YEKEDÜZ E., KARATAŞ G., YAZGAN S. C., KÖKSOY E. B., ÇAY ŞENLER F., UTKAN G., DEMİRKAZIK A., AKBULUT H., ÜRÜN Y.
9. Türk Tıbbi Onkoloji Kongresi, Girne, Cyprus (Kktc), 18 - 22 May 2022, pp.53
- XIII. **Mesane kanserinin oluşumunda ve gelişiminde rol oynayan hub genlerinin biyoinformatik analizle taranması, doğrulanması ve potansiyel prognostik biyobelirteçlerin belirlenmesi**
REZAPOURBEHNAGH S., YEKEDÜZ E., ÜRÜN Y.
9. Türk Tıbbi Onkoloji Kongresi, Girne, Cyprus (Kktc), 18 - 22 May 2022, pp.80
- XIV. **Yeni nesil hormonal tedavi alan metastatik kastrasyon dirençli prostat kanseri hastalarında pan-immün inflamasyon değeri ve sağkalım arasındaki ilişki**
YAZGAN S. C., YEKEDÜZ E., UTKAN G., ÜRÜN Y.
9. Türk Tıbbi Onkoloji Kongresi, Girne, Cyprus (Kktc), 18 - 22 May 2022, pp.79-80
- XV. **Lokalize ewing sarkomlu hastaların demografik ve klinik özelliklerinin değerlendirilmesi ve tedavi sonuçlarının analizi: Tek merkez deneyimi**
KALACI E., KÖKSOY E. B., YEKEDÜZ E., AKBIYIK I., DURSUN B., ÜRÜN Y., UTKAN G.
9. Türk Tıbbi Onkoloji Kongresi, Girne, Cyprus (Kktc), 18 - 22 May 2022, pp.104-105
- XVI. **Tek doz pembrolizumab ile 42 aydır progresyonsuz izlenen küçük hücre dışı akciğer kanseri vakası**
YEKEDÜZ E., UTKAN G., ÜRÜN Y.

5. Gençlerle Onkolojiye Bakış Kongresi, Turkey, 4 - 06 March 2022, pp.45
- XVII. **Kemoterapi, radyoterapi ve RF ablasyon ile uzun süreli tam yanıt izlenen metastatik özofagus kanseri olgusu**
AKBIYIK I., EYLEMER MOCAN E., BALLI S., KAVAK E. E., DURSUN B., KALACI E., YEKEDÜZ E., KÖKSOY E. B., ÜRÜN Y., ÇAY ŞENLER F., et al.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, pp.121
- XVIII. **Everolimus ile klinik yanıtın dört yılın üzerinde olduğu geç nüks timoma & saf eritroid aplazi olgusu**
KÖKSOY E. B., YEKEDÜZ E., KALACI E., DURSUN B., AKBIYIK I., BALLI S., KAVAK E. E., EYLEMER MOCAN E., ÜRÜN Y., UTKAN G., et al.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, pp.71-72
- XIX. **Setuksimab tedavisi alan RAS wild type metastatik sol kolon kanser hastalarında NLR, MCV, MPV'nin sağ kalım ile ilişkisi**
ÖZEL M., KÖKSOY E. B., YEKEDÜZ E., ÜRÜN Y., UTKAN G.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, pp.136
- XX. **Sağ koroner arter oklüzyonu ile saptanan metastatik paraganglioma olgusu**
KÖKSOY E. B., YEKEDÜZ E., ÜRÜN Y., UTKAN G.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, pp.75
- XXI. **CRP/albumin oranının immün denetim noktası inhibitörü alan metastatik kanser hastalarındaki prognostik rolü**
YEKEDÜZ E., YAZGAN S. C., KÖKSOY E. B., AKBULUT H., ÇAY ŞENLER F., DEMİRKAZIK A., UTKAN G., ÜRÜN Y.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, pp.108
- XXII. **Over kanserli hastada nadir bir baş ağrısı nedeni: Varicella zoster ensefaliti**
KALACI E., KÖKSOY E. B., YEKEDÜZ E., DURSUN B., BALLI S., ÜRÜN Y., ÇAY ŞENLER F., UTKAN G.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, pp.110-111
- XXIII. **İyileşen mide ülserinden metastatik mide adenokanser tanısı alan olgu**
EYLEMER MOCAN E., YEKEDÜZ E., ÜRÜN Y., UTKAN G.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, pp.122
- XXIV. **Erken ve geç başlangıçlı metastatik kolorektal kanser hastalarında regorafenib etkinliği ve yan etki profili**
YEKEDÜZ E., YAZGAN S. C., KÖKSOY E. B., ÜRÜN Y., UTKAN G.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, pp.137-138
- XXV. **Metastatik pankreatik nöroendokrin tümörlü olguda ikinci basamakta lanreotid ve metronomik kapesitabin etkinliği**
KÖKSOY E. B., YEKEDÜZ E., KALACI E., DURSUN B., AKBIYIK I., BALLI S., KAVAK E. E., EYLEMER MOCAN E., ÜRÜN Y., ÇAY ŞENLER F., et al.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, pp.125
- XXVI. **Kolorektal kanserli hastalarda RAS mutasyonu ile beden kitle indeksi ve diabetes mellitus arasındaki ilişki**
SÖKMEN M., YEKEDÜZ E., GÜRBÜZ M., KÖKSOY E. B., ÜRÜN Y., UTKAN G.
8. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 3 - 07 November 2021, pp.142-143
- XXVII. **Construction of a New Model to Investigate Breast Cancer Data**
Ağyüz U., PURUTÇUOĞLU GAZİ V., Purutçuoğlu E., ÜRÜN Y.
6th International Conference on Dynamics Games and Science, DGS-VI-2018, 19th Latin American Conference on Economic Theory, JOLATE 2018 and 21st International Consortium on Applied Bioeconomy Research, ICABR 2017, California, United States Of America, 30 May - 02 June 2017, vol.365, pp.11-29
- XXVIII. **Erlotinib Kullanmakta Olan Bir Akciğer Adenokarsinoma Olgusunda Gelişen Skatrisyel Alopesi**
ERTÜRK YILMAZ T., YILDIZHAN İ., HEPER A., ÜRÜN Y., İsmail Mendi B., BOYVAT A.
14. Ege Dermatoloji Günleri, Muğla/Bodrum, Turkey, 1 - 05 May 2019
- XXIX. **Plevral ve peritoneal iyi diferansiye papiller mezotelyoma olgusu**
ÖZYURT N., YEKEDÜZ E., GÜRBÜZ M., YAŞAR H. A., KUBİLAY TOLUNAY P., KARAALIOĞLU B., ÜRÜN Y.

23. Ulusal Kanser Kongresi, Antalya, Turkey, 17 - 21 April 2019, pp.387
- XXX. **Comparison of bone scintigraphy and Ga-68-PSMA PET/CT in the detection of bone metastases of prostate carcinoma**
SOYDAL Ç., NAK D., ARAZ M., AKKUŞ P., ÜRÜN Y., ÖZKAN E., KÜÇÜK N. Ö., KIR K. M.
8th Balkan Congress Nuclear Medicine, 10 - 14 April 2019
- XXXI. **Prognostic importance of serum PSA response in patients who received Lutetium-177 prostate specific antigen treatment for castration resistant prostate cancer**
SOYDAL Ç., ARAZ M., ÜRÜN Y., Nak D., ÖZKAN E., KÜÇÜK N. Ö.
31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Düsseldorf, Germany, 13 - 17 October 2018, vol.45
- XXXII. **MIDE KANSERİ VE ABO KAN GRUBU İLİŞKİSİ: ÇOK MERKEZLİ, GÖZLEMSEL, VAKA-KONTROL ÇALIŞMASI**
YAŞAR H. A., UTKAN G., ÖZDEMİR N., ÇAKMAK ÖKSÜZOĞLU Ö. B., DEDE İ., ÜRÜN Y., AKBULUT H.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, pp.443
- XXXIII. **Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey**
Zengin G., Özyurt N., BEYPINAR İ., Çınkır H. Y., Bilgin B., GÜMÜŞAY Ö., ERTÜRK İ., ŞENDUR M. A. N., UYSAL M., ÜRÜN Y., et al.
ASCO 2018, 1 - 05 June 2018, vol.36, pp.15551
- XXXIV. **Merkel cell carcinoma in Turkey: A multicentric study.**
yıldız f., BÜYÜKŞİMŞEK M., sakalar t., AYDIN Ö., TURNA Z. H., babacan n., arslan ç., ÖZDEMİR N., ÜRÜN Y., UYSAL M., et al.
2018 ASCO Annual Meeting, 1 - 05 June 2018
- XXXV. **NADIR BİR VAKA: SEFUROKSİM KULLANIMI SONRASINDA GELİŞEN RADYASYON RECALL DERMATİTİ**
YAŞAR H. A., KUBİLAY TOLUNAY P., ÜRÜN Y., UTKAN G.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, pp.282
- XXXVI. **SUNITINIB VE ZOLEDRONİK ASIT KULLANIMI İLE GELİŞEN ÇENE OSTEONEKROZU VAKASI**
KUBİLAY TOLUNAY P., YAŞAR H. A., ÜRÜN Y., UTKAN G.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, pp.287
- XXXVII. **TIROZİN KINAZ İNHİBİTÖRÜ İLE TEDAVİ EDİLEN METASTATİK RENAL HÜCRELİ KANSER OLGULARINDA SİSTEMİK İMMÜN İNFLAMASYON İNDEKSİNİN TEDAVİ YANITI İLE İLİŞKİSİ**
BİR YÜCEL K., YAŞAR H. A., UÇAR G., UTKAN G., ÖZDEMİR N., ÜRÜN Y.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, pp.177
- XXXVIII. **SYSTEMIC IMMUNE INFLAMMATION INDEX AND TREATMENT RESPONSE IN PATIENTS WITH METASTATIC RENAL CELL CANCER**
BİR YÜCEL K., YAŞAR H. A., UÇAR G., UTKAN G., ÖZDEMİR N., ÜRÜN Y.
2018 GENITOURINARY CANCERS SYMPOSIUM, SAN-FRANCISCO,CALIFORNIA, United States Of America, 8 - 10 February 2018, vol.36, pp.591
- XXXIX. **Systemic immune inflammation index and treatment response in patients with metastatic renal cell cancer.**
Yacel K. B., Yasar A., Ucar G., Utkan G., Yildirim N., ÜRÜN Y.
Genitourinary Cancers Symposium, San-Francisco, Costa Rica, 8 - 10 February 2018, vol.36
- XL. **Relationship between metabolic parameters and ras mutation status**
KARCI E., SOYDAL Ç., UTKAN G., ÜRÜN Y., AKBULUT H.
30th Annual Congress of the European Association of Nuclear Medicine, 21 - 25 October 2017, vol.44, pp.696
- XLI. **Loneliness and cognitive dysfunction in elderly cancer patients**
Alkan A., Oztoran H. S., Karci E., Tuncay G., Yasar A., Cinar E., ÜRÜN Y., ARAS S., VARLI M., Senler F. C.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28
- XLII. **Experience of 18F Flourodeoxy glucose (FDG) positron emission tomography (PET) - Computed tomography (CT) in testicular carcinoma**
SOYDAL Ç., ÜRÜN Y., NAK D., ÖZKAN E., KÜÇÜK N. Ö.

SNMMI 2017 Annual Meeting, 22 - 26 June 2017, vol.58, pp.1069

XLIII. Can serum prostat specific antigen levels be a predictor for 68Ga PSMA PET/CT positivity?

SOYDAL Ç., ÜRÜN Y., NAK D., ÖZKAN E., KÜÇÜK N. Ö.

SNMMI 2017 Annual Meeting, 22 - 26 June 2017, vol.58, pp.1078

XLIV. Can serum prostat specific antigen levels be a predictor for 68Ga PSMA PET/CT positivity?

SOYDAL Ç., ÜRÜN Y., SÜER E., NAK D., ÖZKAN E., KÜÇÜK N. Ö.

SNMMI 2017 Annual Meeting, Denver, Colorado, United States Of America, 10 - 14 June 2017, vol.58, pp.1078

XLV. Experience of 18F Flourodeoxy glucose (FDG) positron emission tomography (PET)-computed tomography (CT) in testicular carcinoma

SOYDAL Ç., ÜRÜN Y., NAK D., ÖZKAN E., KÜÇÜK N. Ö.

SNM Annual Meeting, Denver, Colorado, United States Of America, 10 - 14 June 2017, vol.58, pp.1069

XLVI. A single center analysis of evolving experience with ALPPS procedure: Towards better patient and graft selection

BALCI D., KIRIMKER E. O., ÖZÇELİK M., ÜSTÜNER E., KONCA C., UTKAN G., AKBULUT H., ÜRÜN Y., ÇAY ŞENLER F., DEMİRKAZIK A., et al.

12th Biennial E-AHPBA Congress 2017, Mainz, Germany, 23 - 26 May 2017

XLVII. Experience of F-18 Flourodeoxy glucose (FDG) positron emission tomography (PET) -computed tomography (CT) in testicular carcinoma

SOYDAL Ç., ÜRÜN Y., NAK D., ÖZKAN E., KÜÇÜK N. Ö.

Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Colorado, United States Of America, 10 - 14 June 2017, vol.58

XLVIII. Can serum prostat specific antigen levels be a predictor for Ga-68 PSMA PET/CT positivity?

SOYDAL Ç., ÜRÜN Y., SÜER E., NAK D., ÖZKAN E., KÜÇÜK N. Ö.

Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Colorado, United States Of America, 10 - 14 June 2017, vol.58

XLIX. Evre III Mide kanseri adjuvant tedavisinde dozetaksel- sisplatin- fluorourasil(DCF) rejiminin etkinliği

ALKAN A., Mızrak D., Karcı E., YAŞAR H. A., KÖKSOY E. B., ÜRÜN M., Kütük T., ÜRÜN Y., ÇAY ŞENLER F., AKYÜREK S., et al.

22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.256-257

L. Kanser tanısı olan ve olmayan geriatrik hastalarda yalnızlık ve kognitif fonksiyonların değerlendirilmesi

ALKAN A., SELVİ ÖZTORUN H., KARCİ E., ÜRÜN Y., Tuncay G., YAŞAR H. A., ÇINAR E., ARAS S., VARLI M., ÇAY ŞENLER F.

22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.247

LI. KANSER TANISI OLAN VE OLMAYAN GERİATRİK HASTALARDA YALNIZLIK VE KOĞNİTİF FONKSİYONLARIN DEĞERLENDİRİLMESİ

ALKAN A., SELVİ ÖZTORUN H., KARCİ E., TUNCAY G., YAŞAR H. A., ÇINAR E., ÜRÜN Y., ARAS S., VARLI M., ÇAY ŞENLER F.

22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017

LII. TRPredictive factors of lymph node metastasis in patients with non metastatic colorectal Adenocarcinoma

Karcı E., KÖKSOY E. B., ALKAN A., Dede İ., Tuncay G., UTKAN G., ÜRÜN Y., AKBULUT H.

ESMO Congress, 7 - 11 October 2016

LIII. Vaccination in oncology practice and predictors

ALKAN A., KARCİ E., YAŞAR H. A., TUNCAY G., ÜRÜN M., KÖKSOY E. B., ÜRÜN Y., ÇAY ŞENLER F., UTKAN G., DEMİRKAZIK A., et al.

ESMO, 7 - 10 October 2016

LIV. Medical oncologists attitudes towards vaccination in oncology practice

ALKAN A., Karcı e., YAŞAR H. A., Tuncay g., ürün m., KÖKSOY E. B., ÜRÜN Y., ÇAY ŞENLER F., UTKAN G., DEMİRKAZIK A., et al.

ESMO annual meeting, 7 - 11 October 2016

- LV. Predictive factors of lymph node metastasis in patients with non-metastatic colorectal adenocarcinoma**
Karci E., Koksoy E. B., Alkan A., Dede I., Tuncay G., Utkan G., ÜRÜN Y., AKBULUT H.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Denmark, 7 - 11 October 2016, vol.27
- LVI. Well differentiated papillary mesothelioma with peritoneal and pleural involvement Case report 8 11 September 2016 P Number 219**
KAYI CANGIR A., SAKALLI M. A., YENİGÜN B. M., ÜRÜN Y., PERÇİNEL S.
26.th World Congress of Cardiothoracic Surgeon, Cape Town, South Africa, 8 - 11 September 2016
- LVII. Severe Drug Interactions and Potentially Inappropriate Medication Usage in Elderly Cancer Patients**
ALKAN A., YAŞAR H. A., KARCI E., KÖKSOY E. B., ÜRÜN M., ÇAY ŞENLER F., ÜRÜN Y., ERGUN H., AKBULUT H.
ASCO, 6 - 10 June 2016
- LVIII. Severe drug interactions and potentially inappropriate medication usage in elderly patients with cancer.**
Alkan A., Yasar A., Karci E., Koksoy E. B., Urun M., Senler F. C., ÜRÜN Y., Ergun H., AKBULUT H.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- LIX. Persistent postmastectomy pain syndrome and posttraumatic stress disorder among breast cancer survivors (ORTHUS study): A study of the palliative care working committee of the Turkish Oncology Group (TOG).**
Alkan A., Guc Z. G., Senler F. C., YAVUZŞEN T., Onur H., Dogan M., Karci E., Yasar A., Koksoy E. B., Tanriverdi O., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- LX. Geriatrik kanser hastalarında ciddi ilaç etkileşimi ve uygunsuz ilaç kullanımı**
ALKAN A., YAŞAR H. A., KARCI E., KÖKSOY E. B., ürün m., ÇAY ŞENLER F., ÜRÜN Y., TUNCAY G., ERGÜN H., AKBULUT H.
6.Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, pp.167
- LXI. Prognostic factors for survival in patients with metastatic melanoma treated with ipilimumab: Turkish Oncology Group (TOG) Study**
ÜRÜN Y., Abali H., Turna H., Esin E., Sedef A. M., Alkan A., Oksuzoglu B., Ozdemir N. Y., Sendur M. A. N., Sezer A., et al.
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51
- LXII. Effect of metformin on sex steroid levels in postmenopausal type 2 diabetic patients**
ÜNLÜTÜRK U., BAKAR F., ÜRÜN Y., NEBİOĞLU S., UYSAL A. R.
17th European Congress of Endocrinology, 16 - 20 May 2015, vol.37
- LXIII. Can primary tumor localization predict the which patient will have benefit from addition of taxanes to platin-5-FU based regimens in metastatic gastric cancer. Multi center retrospective analysis from Turkey, Society of Turkish Oncology Group study**
Kose F., Sedef A. M., Ozdemir N., Gunaldi M., ÜRÜN Y., Besen A. A., Sumbul A. T., SEZGİN GÖKSU S., Dogan O., Mertsoylu H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- LXIV. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum-based chemotherapy: A systematic review and meta-analysis.**
ÜRÜN Y., Leow J. J., Fay A. P., Albiges L., Choueiri T. K., Bellmunt J.
Genitourinary Cancers Symposium, Florida, United States Of America, 26 - 28 February 2015, vol.33
- LXV. Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors.**
Yetisyigit T., Babacan N., ÜRÜN Y., Seber S., Arpacı E., Clhan S., Ylidorim N., Oksuzoglu O. B., Aksoy S., Budakoglu B., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03

June 2014, vol.32

- LXVI. **ABO blood group and risk of lethal prostate cancer**
ÜRÜN Y., Wilson K. M., Shui I. M., Giovannucci E. L., Wolpin B. M., Nguyen P. L., Mucci L. A., Choueiri T. K.
Genitourinary Cancers Symposium, San-Francisco, Costa Rica, 30 January - 01 February 2014, vol.32
- LXVII. **Role of cytoreductive nephrectomy (CN) in patients with metastatic non-clear cell renal cell carcinoma (nccRCC): results from a surveillance, epidemiology, and end results (SEER) database analysis of over 4,900 patients**
Mckay R. R., Aizer A. A., ÜRÜN Y., Kibel A. S., Nguyen P. L., Choueiri T. K.
12th International Kidney Cancer Symposium, Illinois, United States Of America, 25 - 26 October 2013, vol.112, pp.5-6
- LXVIII. **Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC)**
ÜRÜN Y., Gray K. P., Signoretti S., McDermott D. F., Atkins M. B., Lampron M. E., Freedman M., Choueiri T. K., Pomerantz M. M.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- LXIX. **Serum CEA and CA 15-3 levels according to breast cancer subtypes**
Dede I., Utkan G., AKBULUT H., ÜRÜN Y., Mizrak D., Icli F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- LXX. **ABO blood group and the risk of lung cancer: Multicenter, case-control, observational study**
Utkan G., ÜRÜN Y., Cangir A. K., Oksuzoglu O. B., Ozdemir N., Oztuna D., Kocaman G., DEMİRKAZIK A., Okten I., Icli F.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012
- LXXI. **ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study.**
ÜRÜN Y., Koru-Sengul T., Altundag K., Utkan G., Onur H., AKBULUT H., DEMİRKAZIK A., Icli F.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- LXXII. **The Significance of the Serum Leptin Ghreline Tumor Necrosis Factor Alpha and Interleukine 1 Levels in Patient With Non Small Cell Lung Cancer**
ÜRÜN Y., YALÇIN B., KARATAŞ F., UTKAN G., YÜKSEL C., CANGIR A., ÇAY ŞENLER F., DEMİRKAZIK A., AKBULUT H., İÇLİ F., et al.
The 2011 European Multidisciplinary Cancer Congress. Stockholm, Sweden, Stockholm, Sweden, 24 - 27 September 2011, pp.612
- LXXIII. **Status of Granulocyte Colony-Stimulating Factor Receptor in Tumour Tissue of Patients With Breast Cancer**
Yalcin B., Gunaydin Y., Percinel S., Dogan M., ÜRÜN Y., Ozal F. G., Utkan G., AKBULUT H., Icli F., Sencan O.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47
- LXXIV. **The Significance of the Serum Leptin, Ghreline, Tumour Necrosis Factor Alpha and Interleukine-1 Levels in Patients With Non-Small Cell Lung Cancer**
ÜRÜN Y., Yalcin B., Karatas F., Utkan G., YÜKSEL C., Cangir A., Senler F. C., DEMİRKAZIK A., AKBULUT H., Icli F., et al.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47
- LXXV. **Quality of Life Assesment in Patients With Non-Small Cell Lung Cancer Patients Who Have or Have Not Received Second Line Chemotherapy**
Yalcin B., Suna N., Dogan M., ÜRÜN Y., Ozdemir N., Gonullu U., Zengin N., Utkan G., DEMİRKAZIK A., Icli F.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47
- LXXVI. **ABO and Rh Blood Groups Frequency in Women With HER2(+) Breast Cancer**
ÜRÜN Y., Utkan G., Altundag K., Arslan O., Onur H., Arslan U. Y., Kocer M., DOĞAN İ., Yalcin B., Icli F.

- European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47
- LXXVII. **Relationship Between ABO and RH Blood Groups and K-Ras Phenotype in Patients With Colorectal Adenocarcinoma**
ÜRÜN Y., Utkan G., Arslan O., AKBULUT H., Savas B., Senler F. C., Onur H., Yalcin B., DEMİRKAZIK A., Icli F.
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, Sweden, 23 - 27 September 2011, vol.47
- LXXVIII. **Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma**
ÜRÜN Y., Abali H., Oksuzoglu B., Budakoglu B., Yildirim N., Guler T., Ozet G., Zengin N.
49th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 8 - 11 December 2007, vol.110
- LXXIX. **Performing only 2 test have high sensitivity to diagnosis autonomic neuropathy in patients with chronic rena failure on hemodialysis**
Sahin M., Kayatas M., Sennaroglu E., ÜRÜN Y., Akdur S.
42nd Annual Meeting of the European-Renal-Association/European-Dialysis-and-Transplant-Association (ERA-EDTA), İstanbul, Turkey, 4 - 07 June 2005, vol.20

Other Publications

- I. **A Survivorship-Centered Approach to CSI Testicular GCT: How Do Contemporary Approaches Inform Future Practice?**
Bölek H., Yazgan S. C., Yekedüz E., Ürün Y.
Other, pp.1-2, 2024
- II. **ASCO Daily News, Are We Ready to Personalize Treatment for Metastatic Castration-Sensitive Prostate Cancer?**
Yekedüz E., Ürün Y.
Other, pp.1-2, 2023

Metrics

Publication: 247

Citation (WoS): 977

Citation (Scopus): 1233

H-Index (WoS): 15

H-Index (Scopus): 16